Metrics as of 10/17/2026, 01:11 AM (Berlin time), refresh in progress.
Amneal Pharmaceuticals Stock
Amneal Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Chirag K. Patel
- Employees
- 8,700
- Market cap
- $6.1 B
- IPO
- 07/05/2018
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, New Jersey, is a healthcare company involved in the development, licensing, manufacturing, marketing, and distribution of generic and specialty medicinal products. Founded in 2002 as Atlas Holdings, Inc., the company went public on the NASDAQ on May 7, 2018.…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Amneal Pharmaceuticals stock: price history
1D
-0.4%
1W
-3.7%
1M
+6.1%
6M
+37.9%
YTD
+52.2%
1Y
+94.3%
2Y
+120.5%
5Y
+240.1%
10Y
-11.6%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~19% stronger price swings than usual
Amneal Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Amneal Pharmaceuticals is a diversified pharmaceutical company that develops, manufactures, and distributes both generic and specialized brand-name medications. Its portfolio encompasses a broad range of dosage forms including oral, injectable, and transdermal solutions. The business operates through three segments: Generics for complex pharmaceutical formulations, Specialty for proprietary brand products treating diseases such as neurological and endocrine conditions, and AvKARE, which primarily serves government entities. The latter supplies pharmaceuticals and surgical materials through wholesale or unit-dose packaging. Distribution occurs via an extensive network of wholesalers, hospitals, major pharmacy chains, and independent pharmacies in both the United States and international markets.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Amneal Pharmaceuticals
Analyst assessment of Amneal Pharmaceuticals
PRICE TARGET LOW
US$20.00
CONSENSUS
US$23.20
MEDIAN
US$23.00
PRICE TARGET HIGH
US$27.00
0
STRONG BUY
11
BUY
6
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 17/09/2026
Amneal Pharmaceuticals stock metrics
P/E
38.55
P/B
185.39
EV/EBITDA
13.48
RETURN ON EQUITY
174.6%
NET MARGIN
7.2%
DEBT/EQUITY
84.54
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
45.0%
FLOAT SHARES
143,630,420
AVG. DAILY VOLUME (30D)
3,204,298
Insider transactions (SEC)
BUCHI J KEVIN
BUCHI J KEVIN
BOYER ANDREW S
BOYER ANDREW S
Kiely John
Institutional holders
Comparable stocks
Frequently asked questions about Amneal Pharmaceuticals stock
What does Amneal Pharmaceuticals do?
Amneal Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Chirag K. Patel, the company employs around 8,700 people.
The IPO was on 07/05/2018; the stock trades on NASDAQ under the ticker AMRX.
What do analysts say about Amneal Pharmaceuticals stock?
17 analysts rate the stock, the consensus is Buy (as of 17/09/2026).
The average price target is US$23.20, ranging from US$20.00 to US$27.00, with a median of US$23.00.
This is an external assessment, not a statement by Market Jury.
When does Amneal Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 19% stronger than usual.
Does Amneal Pharmaceuticals pay a dividend?
No, Amneal Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Amneal Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Amneal Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Amneal Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.